Cao YX - Search Results

1

Remnant cholesterol as a lipid-lowering target may have a long way to go.

Cao YX, Dou KF, Li JJ. Cao YX, et al. Eur Heart J. 2023 Sep 21;44(36):3481-3482. doi: 10.1093/eurheartj/ehad256. Eur Heart J. 2023. PMID: 37322602 No abstract available.

2

Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention.

Liu HH, Cao YX, Jin JL, Zhang HW, Hua Q, Li YF, Guo YL, Zhu CG, Wu NQ, Xu RX, Chen XH, Li JJ. Liu HH, et al. Among authors: cao yx. J Am Heart Assoc. 2020 Feb 4;9(3):e014581. doi: 10.1161/JAHA.119.014581. Epub 2020 Jan 30. J Am Heart Assoc. 2020. PMID: 32013705 Free PMC article.

3

The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes.

Cao YX, Zhang HW, Jin JL, Liu HH, Zhang Y, Gao Y, Guo YL, Wu NQ, Hua Q, Li YF, Li XL, Xu RX, Cui CJ, Liu G, Dong Q, Sun J, Zhu CG, Li JJ. Cao YX, et al. Cardiovasc Diabetol. 2020 Jul 6;19(1):104. doi: 10.1186/s12933-020-01076-7. Cardiovasc Diabetol. 2020. PMID: 32631321 Free PMC article.

4

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction.

Cao YX, Li S, Liu HH, Zhang M, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Dou KF, Li JJ. Cao YX, et al. Front Cardiovasc Med. 2022 Feb 24;9:797297. doi: 10.3389/fcvm.2022.797297. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35282356 Free PMC article.

5

Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low-density lipoprotein cholesterol in diabetic patients with coronary artery disease.

Dong QT, Gao Y, Wu NQ, Guo YL, Zhu CG, Li S, Liu HH, Cao YX, Zhang HW, Zhao X, Liu G, Dong Q, Li JJ. Dong QT, et al. Among authors: cao yx. J Clin Lab Anal. 2018 Jun;32(5):e22399. doi: 10.1002/jcla.22399. Epub 2018 Jan 30. J Clin Lab Anal. 2018. PMID: 29380428 Free PMC article.

6

Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.

Cao YX, Li JJ. Cao YX, et al. Diabetes Care. 2018 Apr;41(4):e69. doi: 10.2337/dc17-2563. Diabetes Care. 2018. PMID: 29559466 No abstract available.

7

A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels.

Cao YX, Liu HH, Li S, Li JJ. Cao YX, et al. Am J Cardiovasc Drugs. 2019 Feb;19(1):87-97. doi: 10.1007/s40256-018-0303-2. Am J Cardiovasc Drugs. 2019. PMID: 30229525

8

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials.

Cao YX, Li S, Liu HH, Li JJ. Cao YX, et al. BMJ Open. 2018 Oct 4;8(9):e022348. doi: 10.1136/bmjopen-2018-022348. BMJ Open. 2018. PMID: 30287608 Free PMC article.

9

[No title available]

[No authors listed] [No authors listed] PMID: 31604401

10

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.

Cao YX, Jin JL, Sun D, Liu HH, Guo YL, Wu NQ, Xu RX, Zhu CG, Dong Q, Sun J, Li JJ. Cao YX, et al. J Transl Med. 2019 Nov 11;17(1):367. doi: 10.1186/s12967-019-2123-9. J Transl Med. 2019. PMID: 31711505 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

454 results

Search Page